Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028415 · ClinicalTrials.gov registry record · NA
AMPLEX Ankle Fusion and Hindfoot
A NA study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT03028415 is a NA study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT03028415, a NA study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
To demonstrate that AMPLEX is non-inferior to autogenous bone graft (ABG) for bone fusion in a population indicated for single, double, or triple hindfoot arthrodesis or ankle arthrodesis surgery with supplemental graft material.
Interventions
- DEVICE AMPLEX
- PROCEDURE Autogenous Bone Graft (ABG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2020-07-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028415
The ClinicalTrials.gov registry entry for NCT03028415 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMPLEX is the first listed.
NCT03028415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028415 about?
NCT03028415 is a clinical study titled "AMPLEX Ankle Fusion and Hindfoot". To demonstrate that AMPLEX is non-inferior to autogenous bone graft (ABG) for bone fusion in a population indicated for single, double, or triple hindfoot arthrodesis or ankle arthrodesis surgery with supplemental graft material.
What is the current status of trial NCT03028415?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2017-07-28. Estimated completion is 2020-07-09.
What interventions are being tested in trial NCT03028415?
The interventions under investigation include: AMPLEX (DEVICE), Autogenous Bone Graft (ABG) (PROCEDURE).
Who is sponsoring clinical trial NCT03028415?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.